Michael Auerbach
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Michael Auerbach has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Harold Ballard
New York University School of Medicine, New York, NY
6 shared publicationsAlice Maniatis
2 shared publicationsDan Picard
2 shared publicationsLawrence Tim Goodnough
2 shared publicationsAlan Ackerman
From Averbach Hematology-Oncology, Baltimore, MD; New York University School of Medicine, New York, NY; Department of Statistics, Rutgers University, New Brunswick; Watson Laboratories, Morristown, NJ; Mount Sinai Medical Center, Miami Beach, FL; Mount Ayr Medical Center, Mount Ayr, IA
1 shared publicationDan Coyne
Division of Nephrology, Professor of Medicine, Washington University School of Medicine, St. Louis, Missouri
1 shared publication
Latest Publications
- 1 November 2016
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 68 (5) , 665-666
Oral Iron Therapy: After Three Centuries, It Is Time for a Change
- 1 November 2016
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 68 (5) , 665-666
Oral Iron Therapy: After Three Centuries, It Is Time for a Change
- 16 January 2011
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 56 (4) , 511-512
Should intravenous iron be upfront therapy for iron deficiency anemia?
- 16 January 2011
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 56 (4) , 511-512
Should intravenous iron be upfront therapy for iron deficiency anemia?
- Open Access
- 4 December 2010
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2010 (1) , 338-347
Clinical Use of Intravenous Iron: Administration, Efficacy, and Safety
This section reviews the history, pharmacology, administration, efficacy, and toxicity of intravenous iron. Intravenous iron offers advantages over oral iron for the treatment of iron deficiency anemia across a wide range of disease states associated with absolute and functional iron deficiency. However, there remain concerns about the acute safety profiles of the available preparations and the potential for long-term toxicity with their repeated administration. Seven intravenous iron formulations are available. Confusion concerning the relative toxicities of the different formulations abounds. The similarities and differences are discussed. Iron repletion has been associated with adverse outcomes in infections. The relationship, if any, between intravenous iron administration and infections is reviewed. The potential advantages of total dose infusion (TDI), complete repletion in a single setting, are highlighted. A new paradigm for iron replacement therapy in iron deficiency anemia is presented.
- 4 December 2010
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2010 (1) , 338-347
Open AccessClinical Use of Intravenous Iron: Administration, Efficacy, and Safety
This section reviews the history, pharmacology, administration, efficacy, and toxicity of intravenous iron. Intravenous iron offers advantages over oral iron for the treatment of iron deficiency anemia across a wide range of disease states associated with absolute and functional iron deficiency. However, there remain concerns about the acute safety profiles of the available preparations and the potential for long-term toxicity with their repeated administration. Seven intravenous iron formulations are available. Confusion concerning the relative toxicities of the different formulations abounds. The similarities and differences are discussed. Iron repletion has been associated with adverse outcomes in infections. The relationship, if any, between intravenous iron administration and infections is reviewed. The potential advantages of total dose infusion (TDI), complete repletion in a single setting, are highlighted. A new paradigm for iron replacement therapy in iron deficiency anemia is presented.
- 1 November 2008
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 52 (5) , 826-829
Ferumoxytol as a New, Safer, Easier-to-Administer Intravenous Iron: Yes or No?
- 1 November 2008
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 52 (5) , 826-829
Ferumoxytol as a New, Safer, Easier-to-Administer Intravenous Iron: Yes or No?
- 1 July 2008
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 6 (6) , 585-592
Intravenous Iron in Oncology
Intravenous iron (IV Fe) as an adjunct to therapy with erythropoiesis-stimulatory agents (ESAs) is standard care in dialysis-associated anemia, adding huge increments in hemoglobin and hematopoietic responses and decreased transfusions without significant toxicity. Cost savings, decreased exposure to ESAs, and decreased times to reach target hemoglobins are realized. Although similar benefits have been seen in all studies performed in patients with chemotherapy-induced anemia (CIA), experts are reluctant to incorporate routine use of IV Fe into treatment, largely because of misinterpretation and misunderstanding of the clinical nature of adverse events reportedly associated with its administration. IV Fe is therefore underused in oncology patients with anemia. Published experience with more than 1000 patients in clinical trials involving the use of IV Fe suggests minimal toxicity and substantial benefit are experienced when high molecular weight iron dextran is avoided. This article presents evidence recommending routine incorporation of IV Fe into treatment for CIA.
- 1 July 2008
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 6 (6) , 585-592
Intravenous Iron in Oncology
Intravenous iron (IV Fe) as an adjunct to therapy with erythropoiesis-stimulatory agents (ESAs) is standard care in dialysis-associated anemia, adding huge increments in hemoglobin and hematopoietic responses and decreased transfusions without significant toxicity. Cost savings, decreased exposure to ESAs, and decreased times to reach target hemoglobins are realized. Although similar benefits have been seen in all studies performed in patients with chemotherapy-induced anemia (CIA), experts are reluctant to incorporate routine use of IV Fe into treatment, largely because of misinterpretation and misunderstanding of the clinical nature of adverse events reportedly associated with its administration. IV Fe is therefore underused in oncology patients with anemia. Published experience with more than 1000 patients in clinical trials involving the use of IV Fe suggests minimal toxicity and substantial benefit are experienced when high molecular weight iron dextran is avoided. This article presents evidence recommending routine incorporation of IV Fe into treatment for CIA.
- 1 July 2008
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 48 (4) , 455-457
Intravenous iron as standard of care in oncology: Opportunity lost
- 1 July 2008
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 48 (4) , 455-457
Intravenous iron as standard of care in oncology: Opportunity lost
- 1 May 2008
- Published by Wiley in Transfusion
- Vol. 48 (5) , 988-1000
The role of intravenous iron in anemia management and transfusion avoidance
- 1 May 2008
- Published by Wiley in Transfusion
- Vol. 48 (5) , 988-1000
The role of intravenous iron in anemia management and transfusion avoidance
- 12 March 2008
- Published by Wiley in Transfusion
- Vol. 48 (5) , 988-1000
The role of intravenous iron in anemia management and transfusion avoidance
- 12 March 2008
- Published by Wiley in Transfusion
- Vol. 48 (5) , 988-1000
The role of intravenous iron in anemia management and transfusion avoidance
- 1 March 2008
- Published by Elsevier in Kidney International
- Vol. 73 (5) , 528-530
Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease
- 1 March 2008
- Published by Elsevier in Kidney International
- Vol. 73 (5) , 528-530
Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease
- 13 February 2008
- Published by Wiley in American Journal of Hematology
- Vol. 83 (7) , 580-588
Intravenous iron: From anathema to standard of care
A growing body of literature supports the use of intravenous iron as a compliment to erythropoiesis stimulatory therapy and in a significant number of disease states where iron is necessary and oral iron is ineffective or not tolerated. The differences in efficacy, safety, and clinical nature of serious adverse events that occur with the various iron preparations are poorly understood. Misinterpretation of adverse events leads to underutilization of this important treatment modality. Understanding the history of the development and use of intravenous iron is crucial to appreciate its importance in the management of anemias of dialysis, cancer, and cancer chemotherapy and properly assess side effects and toxicity. The benefits seen with intravenous iron therapy are independent of the pretreatment levels of serum ferritin, iron, total iron binding capacity, and percent transferrin saturation. Intravenous iron has been shown to overcome hepcidin induced iron restricted erythropoiesis in iron‐replete patients. Available clinical and experimental data suggest that increased utilization of intravenous iron should be considered. Am. J. Hematol., 2008.
- 13 February 2008
- Published by Wiley in American Journal of Hematology
- Vol. 83 (7) , 580-588
Intravenous iron: From anathema to standard of care
A growing body of literature supports the use of intravenous iron as a compliment to erythropoiesis stimulatory therapy and in a significant number of disease states where iron is necessary and oral iron is ineffective or not tolerated. The differences in efficacy, safety, and clinical nature of serious adverse events that occur with the various iron preparations are poorly understood. Misinterpretation of adverse events leads to underutilization of this important treatment modality. Understanding the history of the development and use of intravenous iron is crucial to appreciate its importance in the management of anemias of dialysis, cancer, and cancer chemotherapy and properly assess side effects and toxicity. The benefits seen with intravenous iron therapy are independent of the pretreatment levels of serum ferritin, iron, total iron binding capacity, and percent transferrin saturation. Intravenous iron has been shown to overcome hepcidin induced iron restricted erythropoiesis in iron‐replete patients. Available clinical and experimental data suggest that increased utilization of intravenous iron should be considered. Am. J. Hematol., 2008.